Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial

Anirudh Kumar, Divyang R Patel, Danielle M Brennan, Kathy E Wolski, A Michael Lincoff, Giacomo Ruotolo, Ellen McErlean, Govinda Weerakkody, Jeffrey S Riesmeyer, Stephen J Nicholls, Steven E Nissen, Venu Menon, Anirudh Kumar, Divyang R Patel, Danielle M Brennan, Kathy E Wolski, A Michael Lincoff, Giacomo Ruotolo, Ellen McErlean, Govinda Weerakkody, Jeffrey S Riesmeyer, Stephen J Nicholls, Steven E Nissen, Venu Menon

Abstract

Background The failure of cholesteryl ester transfer protein inhibitor torcetrapib was associated with an off-target increase in plasma aldosterone. We sought to evaluate the impact of evacetrapib on plasma aldosterone level and determine the association between plasma aldosterone level and major adverse cardiovascular events among patients with stable high-risk vascular disease enrolled in the ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High Risk for Vascular Outcomes) trial. Methods and Results We included all patients with a plasma aldosterone level (N=1624) and determined the impact of evacetrapib exposure compared with placebo on plasma aldosterone levels after 12 months of treatment. Using baseline and postexposure aldosterone levels, hazard ratios for major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, cerebrovascular accident, hospitalization for unstable angina, and revascularization) with increasing quartile of baseline and percentage change in plasma aldosterone level at follow-up were calculated. The average age was 65.2 years, 75.7% were men, 93.7% were hypertensive, 73.3% were diabetic, and 57.6% had a prior myocardial infarction. Baseline plasma aldosterone level (85.2 [43, 150] versus 86.8 [43, 155] pmol/L; P=0.81) and follow-up percentage change (13.6% [-29, 88] versus 17.9% [-24, 87]; P=0.23) were similar between those who received evacetrapib and placebo. During median follow-up of 28 months, major adverse cardiovascular events occurred in 263 patients (16.2%). The hazard ratios for increasing quartile of baseline or percentage change in plasma aldosterone level at follow-up were not significant for major adverse cardiovascular events. These findings remained consistent when adjusting for significant characteristics. Conclusions Exposure to evacetrapib did not result in significant change in plasma aldosterone levels compared with placebo. Among patients with stable high-risk vascular disease, plasma aldosterone levels were not a predictor for future cardiovascular events. Clinical Trial Registration URL: http://www.ClinicalTrials.gov. Unique identifier: NCT01687998.

Keywords: aldosterone; cholesteryl transfer protein inhibitors; major adverse cardiovascular events.

Figures

Figure 1
Figure 1
Differences in plasma aldosterone levels at baseline and 12‐month follow‐up by treatment group.
Figure 2
Figure 2
Kaplan‐Meier curves for major adverse cardiovascular events (MACEs; cardiovascular [CV] death, nonfatal myocardial infarction [MI], cerebrovascular accident, hospitalization for unstable angina [UA], and revascularization), all‐cause mortality, and the triple end point by quartile of baseline plasma aldosterone level.

References

    1. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez‐Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.
    1. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal‐OUTCOMES Investigators . Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099.
    1. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva‐Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators . Evacetrapib and cardiovascular outcomes in high‐risk vascular disease. N Engl J Med. 2017;376:1933–1942.
    1. REVEAL Collaborative Group , Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
    1. Rios FJ, Neves KB, Nguyen Dinh Cat A, Even S, Palacios R, Montezano AC, Touyz RM. Cholesteryl ester‐transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox‐dependent processes. J Pharmacol Exp Ther. 2015;353:27–34.
    1. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit‐Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694–2701.
    1. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthelemy O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST‐elevation myocardial infarction. Circulation. 2006;114:2604–2610.
    1. Beygui F, Montalescot G, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J; OPERA Investigators . Aldosterone and long‐term outcome after myocardial infarction: a substudy of the French nationwide OPERA study. Am Heart J. 2009;157:680–687.
    1. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006;114:2572–2574.
    1. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, Richards AM. Plasma aldosterone levels during hospitalization are predictive of survival post‐myocardial infarction. Eur Heart J. 2008;29:2489–2496.
    1. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Eur Heart J. 2010;31:1237–1247.
    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–717.
    1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321.
    1. Di Pasquale P, Cannizzaro S, Scalzo S, Parrinello G, Fasullo S, Giambanco F, Fatta A, Paterna S. Effects of canrenoate plus angiotensin‐converting enzyme inhibitors versus angiotensin‐converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. Am Heart J. 2005;150:919.
    1. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F; REMINDER Investigators . Early eplerenone treatment in patients with acute ST‐elevation myocardial infarction without heart failure: the Randomized Double‐Blind REMINDER Study. Eur Heart J. 2014;35:2295–2302.
    1. Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Riesmeyer J, Vangerow B, Ruotolo G, Weerakkody GJ, Nissen SE. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high‐risk for vascular outcomes: rationale and design of the ACCERLATE trial. Am Heart J. 2015;170:1061–1069.
    1. Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda‐Takemura K, Matsuzawa Y. Large and cholesteryl ester‐rich high‐density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency cannot protect macrophages from cholesterol accumulation induced by acetylated low‐density lipoproteins. J Biochem. 1994;116:257–262.
    1. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17:594–603.
    1. Sloop GD, Weidman JJ, St Cyr JA. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity? Ther Adv Cardiovasc Dis. 2015;9:32–35.
    1. van Capelleveen JC, Bernelot Moens SJ, Yang X, Kastelein JJP, Wareham NJ, Zwinderman AH, Stroes ESG, Witztum JL, Hovingh GK, Khaw KT, Boekholdt SM, Tsimikas S. Apolipoprotein C‐III levels and incident coronary artery disease risk: the EPIC‐Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2017;37:1206–1212.
    1. Jørgensen AB, Frikke‐Schmidt R, Nordestgaard BG, Tybjærg‐Hansen A. Loss‐of‐function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.
    1. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005;16:104–107.
    1. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33–41.
    1. Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Tanaka Y, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yoneda T, Hashimoto S, Yanase T, Suzuki T, Kawamura T, Tabara Y, Matsuda F, Naruse M; Nagahama Study . Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension. 2018;71:530–537.
    1. Monticone S, Burrello J, Tizzani D, Berello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol. 2017;69:1811–1820.
    1. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow‐up study. J Clin Endocrinol Metab. 2006;91:3457–3463.
    1. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007;30:2349–2354.
    1. Pitts R, Gunzburger E, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, Nicholls SJ, Shah PK, Tardif JC, Olsson AG, McMurray JJ, Kittelson J, Schwartz GG. Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure. J Am Heart Assoc. 2017;6:e004119 DOI: 10.1161/JAHA.116.004119.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅